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Cannabis is the most prevalent illicit drug amongst adolescents worldwide. Over the past 40 
years, changes in cannabis potency (rising concentrations of delta-9-tetrahydrocannabiol, 
‘THC’ and/or decreases in cannabidiol, ‘CBD’) have occurred. Epidemiological and experi-
mental evidence demonstrates that cannabis with high THC and little if any CBD is associ-
ated with an increased risk of psychotic outcomes, an impact on spatial working memory and 
prose recall, and increased reports of severity of cannabis dependence.  However, many stud-
ies have failed to address adolescence, the peak age at which individuals typically try canna-
bis - and may be the most vulnerable age to experience cannabis harms. In this review, we 
highlight the importance of changing cannabis products on adolescent health, and the impli-












Cannabis is the most widely used illicit drug worldwide, with approximately 183·3 million 
users, making up nearly 4% of the global population1. Despite a decline in prevalence of use, 
cannabis is being used with greater frequency, for instance, in the United States, one in sev-
enteen 12th graders (17-18 years) reported daily cannabis use, a rate that has increased since 
20072. It is estimated that 13 million people worldwide meet clinical criteria for a Cannabis 
Use Disorder - a problematic pattern of persistent use causing clinically significant impair-
ment or distress - accounting for a global burden of disease of two million disability adjusted 
life years3. This burden peaks in late adolescence (age 20-24) and is highest in the United 
States, Canada, Australia, New Zealand and Western European countries such as the United 
Kingdom3. In Europe, the number of first-time clients entering specialist drug treatment for 
cannabis increased from 43,000 in 2005 to 76,000 in 20154 with rising trends in 16 of the 22 
European countries providing eligible data5. While the explanation for this is unclear, it may 
be due to factors such as greater detection rates, improved pathways for referral, and changes 
in stigma towards mental health and treatment. An alternative explanation, however, suggests 
that this may be a result of an increase in cannabis potency (rising delta-9-tetrahydrocanna-
binol; ‘THC’ and/or decreasing cannabidiol; ‘CBD’)6. In light of widespread policy change in 
parts of the USA and Canada, resulting in the legalisation of medicinal and recreational can-
nabis (potentially changing the availability of cannabis products to millions of young people) 
and marked increases in the potency of cannabis products7,8, understanding the effects of var-
iation in cannabis potency on adolescent mental health, cognition, and development is of par-
amount importance. This will not only inform etiologic models of cannabis use and psychiat-
ric comorbidity but will also allow for the design of evidence-based prevention programs tar-
geting adolescent cannabis use. The World Health Organization (WHO) defines adolescence 
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as ranging between 10-19 years and young people as ranging between 10-24 years. This re-
view includes research referring to both adolescents and young people recognizing the signif-
icance of shifting social determinants on later adolescent development9.  
Firstly this review will focus on the role of cannabis on the endocannabinoid system, com-
monly discussed cannabis constituents, and global trends in cannabis potency. Secondly, we 
will examine whether adolescents appear to be more susceptible to rising levels of THC 
(and/or lower levels of CBD) in cannabis. Thirdly, we will review evidence concerning the 
possible impact of increasing cannabis potency on adolescent neurocognition and mental 
health. Lastly, the review aims to highlight the importance of cannabis potency within clini-
cal and educational policy and practice as well as making recommendations for future re-
search. 
Global changes in cannabis potency and cannabis markets  
The effects of cannabis and its exogenous cannabinoids (including THC and CBD) occur pri-
marily through interaction with the endocannabinoid system10. The endocannabinoid system 
includes cannabinoid receptors (CB1R and CB2R), their endogenous ligands including anan-
damide (AEA) and 2-arachidonoylglycerol (2-AG), and enzymes such as Fatty Acid Amide 
Hydrolase, which breaks down AEA and 2-AG. The endocannabinoid system regulates nu-
merous biological processes involved in development and neuroplasticity early in life, as well 
as playing a critical role in regulating synaptic plasticity10. CB1Rs are densely located in key 
brain regions involved in cognition, reward, and adolescent neurodevelopment such as the 
hippocampus, basolateral amygdala, nucleus accumbens, and the prefrontal cortex (PFC)11. 
With it occupying a broad spatial area of the developing brain, the endocannabinoid system 
plays a key role in age-related changes in the brain throughout the lifespan10. During the im-
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portant time of neuromaturation, the brain may be more vulnerable to disturbances from ex-
ogenous cannabinoids, which may have a supraphysiological effect on endocannabinoid re-
ceptors, and thus alter normal brain functioning12. 
While cannabis contains a wide range of cannabinoids, the most commonly discussed are 
THC and CBD. THC acts as a partial agonist at CB1 receptors, while cannabidiol (CBD) has 
low affinity for CB1R, but can attenuate CB1R agonist effects and inhibit the reuptake and 
hydrolysis of endocannabinoids11. THC is the main psychoactive component responsible for 
the ‘high’ users seek, and has been found to have dose-dependent effects on memory, atten-
tion, and verbal fluency, as well as contributing to transient paranoid-like symptoms in labor-
atory studies13. By contrast, CBD is non-intoxicating and has been found to offset the harm-
ful effects on verbal memory impairment and psychotic symptoms14,15. Concentrations of 
THC and CBD are known to vary across cannabis plants due to variation in genetics, growing 
conditions, preparation and extraction16,17. For instance, unfertilized female plants yield a 
more potent product, as the plant converts its energy to cannabinoid synthesis rather than 
seed production18. Referred to as sinsemilla (Spanish for “without seeds”) (see Fig. 1), and 
commonly called ‘skunk’ in the UK or ‘nederwiet’ in the Netherlands, this highly potent type 
of cannabis has been found to contain THC ranging from 1·9% to 22·5% (Mean 14%), with 
minimal CBD19. A less potent type, seeded herbal cannabis, can range between 1·8% and 
5·7% THC (Median 3.5%), whereas resin, compressed preparations of plant matter, can vary 
greatly in THC content (0% - 29·3% Mean 6.3%). An emerging cannabis product that is less 
common, but often extremely potent, is cannabis concentrates (see Fig. 1). Concentrates are 
produced via a range of extraction techniques (including butane, super-critical carbon diox-
ide, and combined heat and pressure), and as a result, differ in texture and appearance. They 
have also been found to vary greatly in THC and CBD, according to the extraction technique. 
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One particular study20 in the US assessed the CBD and THC content of 57 concentrate sam-
ples at a medical cannabis market. It was found that they contained between 23·7% and 
75·9% THC (Mean 63.4%), with all but five samples having low levels (<5%) of CBD20. 
In addition to recent advances in cannabis production and extraction techniques, New Psy-
choactive Substances (NPS) have also entered the drug market21. Synthetic cannabinoids 
elicit cannabimimetic effects similar to natural cannabis. However, while THC acts as a par-
tial agonist, synthetic cannabinoids typically act as full agonists at cannabinoid receptors22. 
As a result, synthetic cannabinoids produce physiological (e.g. nausea) and psychiatric (e.g. 
anxiety, psychosis) effects that are considerably more intense than cannabis22, and can result 
in more serious adverse events such as seizures and even death23. A thorough discussion of 
synthetic cannabinoids is beyond the scope of this review, which focuses on cannabis and its 
constituent cannabinoids. 
The cannabis market in the US, Australia, and parts of Europe have shown to be dominated 
by high potency cannabis with high levels of THC and little if any CBD8,17,19,24. Over the past 
40 years, THC levels in cannabis have steadily increased worldwide, with average THC in 
2009 being over nine times greater than in 197025. This is consistent with data from cannabis 
seizures in the UK, where high potency sinsemilla cannabis made up 15% of police seizures 
in 1999-200226, 50·6% in 2004–2005, 84·5% in 2007–2008, and 93·6% in 201619. Trends to-
wards high potency sinsemilla cannabis are reflected in seizure data in the US8 and Aus-
tralia17, with average total THC content of 12% and 14% respectively, along with reductions 
in CBD content in the US8. Furthermore, figures from Washington State in the US show that 
concentrated cannabis extracts made up 21·2% of the market within two years of legal sales, 
suggesting a significant demand for extremely potent forms of cannabis9. Another notable 
change in legal cannabis markets has been the dramatic decrease in potency adjusted price 
over time (both at the retail and supply level)9. As price decreases, the price per unit of THC 
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also drops, and this might be expected to encourage purchasing behavior and increase expo-
sure to THC27. Therefore, increased levels of harm might be attributed to a decline in the po-
tency-adjusted price per unit of THC, and the increase in potency.. 8 
Why might adolescents be more susceptible to increases in cannabis potency?    
Adolescence is a critical time for growth and development. This phase involves a distinct pe-
riod of biological change, even beyond puberty, where a series of hormonal cascades lead to 
both cognitive and physical changes28. There is an expansion of the social self, an introduc-
tion to romantic and professional relationships, as well as an understanding of one’s identity 
and role within contexts. Adolescence is marked by a period of dramatic cognitive develop-
ment, where the brain undergoes neuronal maturation and cortical restructuring via processes 
of cortical thinning, synaptic reorganisation, and myelination of white matter tracts29. There 
are major changes in the PFC, hippocampus, amygdala, and the nucleus accumbens, areas 
which are responsible for harm avoidance, inhibition, decision making, learning and memory, 
emotion, motivation and reward29. While cortical functions are still under development, al-
ready developed reward related circuitry leads to the propensity for adolescents to seek nov-
elty and reward in the face of uncertainty or potential negative outcomes, such as alcohol and 
illicit drugs29. The inability to control one’s behavior, i.e. impulsivity, is often implicated in 
early onset adolescent drug use30.  Behavioral inhibition tasks such as the Stop-Signal task 
(SST)31 and the Go/No-Go task measure the ability (or inability) to suppress a task-induced 
response to a ‘Go’ stimulus. The results of neuroimaging and cognitive studies using SST and 
Go/No-Go tasks have revealed an association between impairment in neural responses on 
these tasks and the risk for adolescent substance use32-34. 
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One such study concluded that adolescent cannabis users exerted greater neurocognitive ef-
fort, despite similar performance to adolescent non-cannabis users35. During the inhibition tri-
als of a Go/No-Go task, cannabis users showed greater activation in the right dorsolateral pre-
frontal, bilateral medial frontal, bilateral inferior, superior parietal lobules, and right occipital 
gyrus compared to the comparison group. These brain regions are implicated in sustained at-
tention36, suggesting that users had to recruit more attentional resources in order to complete 
the tasks successfully. During the non-inhibitory trials, cannabis users showed greater activity 
in right prefrontal, insular and parietal cortices. Interestingly, abnormal activation of insular 
cortices has been found to be associated with a reduced awareness of internal and external 
cues, such as the ability to recognise ones’ own substance use as problematic. It is therefore 
believed that abnormal activation of insular cortices plays a role in problematic substance 
use37.   
Behan et al.32 also showed that adolescent cannabis users produced fewer successful inhibi-
tion trials in a Go/No-Go task compared to the non-cannabis users. Furthermore, a positive 
correlation between self-reported cannabis amount in the past week/month and parietal, bilat-
eral cerebellar, and right frontal connectivity was shown, suggesting that the cerebellum is 
compensating when other task related regions are not engaged. While compensatory efforts 
have yielded similar results to controls in other studies38, worse performances by cannabis us-
ers in Behan et al.32 are consistent with the hypothesis that increased engagement of the cere-
bellum during response inhibition is associated with poorer task performance. Overall, the 
available literature suggests that cannabis users require additional neural resources to perform 
as well as non-users in cognitive inhibition tasks. In conclusion, and as illustrated in Fig. 2, 
adolescent developmental processes such as neuromaturation and predisposing factors such 
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as cognitive inhibition, impulsivity and reward sensitivity play a major role in the susceptibil-
ity of adolescents to the harmful effects of cannabis use. Whether these preceding risk factors 
influence the type of cannabis used is a question that has yet to be investigated.  
 
The impact of cannabis potency on adolescent health 
Epidemiological studies have consistently demonstrated that cannabis use in adolescence is 
associated with an increased risk of psychotic symptoms39-43, anxiety44 and in some cases de-
pression45. The onset and magnitude of the effects of cannabis use on neurological function 
remains under debate. A recent review of longitudinal studies reported that early cannabis use 
was prospectively associated with neurocognitive decline particularly in IQ and episodic 
memory, with the greatest decline occurring in daily users46. However, almost all studies 
have categorised users according to frequency of cannabis use, and few studies have em-
ployed measures examining the impact of high versus low potency on either neurocognitive 
function or mental health outcomes. Morgan et al.15 compared psychotic-like symptoms in 54 
recreational cannabis users with 66 daily cannabis users aged 16-23 years. The results re-
vealed lower psychotic symptoms in individuals with hair samples containing CBD compared 
with those without, however this effect was only seen in recreational users with high levels of 
THC in their hair. These findings suggest that CBD modulates the psychotic-like effects of 
THC, but that frequent users may be tolerant to these protective effects of CBD on THC 
harms. In a case control study of patients and controls aged between 18-65 years with first 
episode psychosis, Di Forti et al.47 showed that compared to non-cannabis users, individuals 
who used skunk-like cannabis (high THC, minimal CBD) daily were more than 5-times as 
likely to be diagnosed with a psychotic disorder compared to non-cannabis users. Moreover, 
frequent use of high potency cannabis use was found to be associated with an increased risk 
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of relapse following first-episode psychosis48. These findings are consistent with experi-
mental evidence suggesting that the psychotomimetic effects of THC are dose-dependent13 
and may be offset by CBD14. Overall, these studies clearly show the importance of highlight-
ing the risk of high-potency cannabis products, particularly for adolescents who might be sus-
ceptible to the development of psychotic symptoms. 
Few studies have accounted for cannabis type when assessing depression and anxiety in ado-
lescent cannabis users. An anonymous global drug survey of young people (18> years) re-
vealed that those with a lifetime diagnosis of depression and anxiety were significantly more 
likely to use high potency cannabis, in particular Butane Hash Oil (BHO)49. BHO is a canna-
bis extract that is frequently sold with high levels of THC, and relatively little CBD20. How-
ever, it must be noted that this study is cross-sectional and uses a lifetime diagnosis, which 
makes the existence and direction of causality difficult to establish16. A second cross-sec-
tional study15 had similar findings, with higher depression and anxiety scores reported in rec-
reational and daily cannabis users (aged 16-23) with high levels of THC in hair samples, alt-
hough this may have been attributable to increased levels of use and/or use of higher potency 
products.  
A small number of studies have investigated the association between high and low potency 
cannabis and cannabis related problems. Freeman and Winstock50 using the same data from 
the anonymous global drug survey revealed that young people reporting frequent use of high 
potency cannabis was associated with a greater severity of cannabis dependence. A 16-year 
study in the Netherlands6 found an association between changes in THC concentrations in 
cannabis sold at national retail outlets and the number of people entering specialist drug treat-
ment for cannabis problems. However, given that the majority of studies were cross-sec-
tional, longitudinal studies are needed to investigate the existence and direction of potential 
causal relationships between cannabinoids and mental health outcomes in young people.   
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Cannabis use behaviours in adolescence 
Whilst high potency cannabis is associated with greater harms compared to low potency can-
nabis in equal quantities what must be considered is whether cannabis users adjust (or ‘ti-
trate’) their consumption according to THC/CBD levels. A handful of recent studies have ex-
plored such as possibility in young cannabis users512-53. Identified by a cluster analysis based 
on demographics, cannabis user and consumption characteristics, Korf et al.51 found that the 
‘strongest high’ group consisted mostly of younger participants (Mean age 22.65 yrs) who 
were least likely to report titration (reducing the number of grams used, depth of inhalation, 
or pace of smoking) in response to rising cannabis potency. Additionally, some members of 
this group actually reported using more cannabis as potency rose, further enhancing their ex-
posure to THC. In a subsequent Dutch study assessing titration in an ecological setting, van 
der Pol et al.52 discovered that THC concentration in users’ own cannabis was positively cor-
related with the amount of cannabis they added to their joints. However, THC concentration 
was negatively correlated with inhalation volume, reducing THC exposure. Therefore, those 
who used higher potency cannabis tended to make larger joints, but partially engaged in titra-
tion by lowering their inhalation volume. The concept of partial titration was also supported 
by an ecological study of adolescent cannabis users (aged 16-24) in the UK53.  That study 
found that as THC concentrations rose, users added less cannabis to their joints, partially re-
ducing the effects of increased potency. However, they did not adjust their behavior accord-
ing to concentrations of CBD in their cannabis. Measures of titration may also be important 
for identifying risk of transition to problematic use. A follow up of the Dutch study con-
ducted by van der Pol et al. found that smoking topography while using cannabis (increased 
puff volume and duration) predicted the severity of cannabis dependence 1·5 years later after 
adjusting for baseline levels of dependence52.  Taken together, these findings suggest that 
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cannabis users may partially (but not completely) adapt to changes in potency by titrating ei-
ther the amount they add to their joints, and/or their inhalation. The contrasting effects of 
cannabis between adults and adolescents is further highlighted by Mokrysz et al.54. When 
measuring a range of acute effects following the inhalation of vaporized active or placebo 
cannabis, it was found that adolescent participants (16-17 years) felt less ‘stoned’ and experi-
enced lower psychotic like symptoms and anxiety compared to adults (24-28 years). Further-
more, adults demonstrated a greater impairment in reaction time on spatial working memory 
and prose recall tasks. Moreover, where adults expressed satiety, adolescents did not, instead 
wanting more cannabis regardless of taking the active or placebo drug. It could therefore be 
suggested that the increased drive for the rewarding properties of cannabis is a possible con-
tributing factor to escalating use in young people54. In conclusion, cannabis use behaviour, 
such as understanding cannabis potency, titration, satiety and acute cannabis effects, are im-
portant factors to consider when assessing the harms of cannabis use in adolescents. While 
future research must account for cannabis type, cannabis use behaviours also contribute to 
determining the amount of THC consumed by young people, and thus the potential harms 
they are exposed to.  
 
Limitations 
Even though evidence from several US states and countries report increases in cannabis po-
tency, there are a number of limitations. Firstly, the majority of data is based on police sei-
zures, which may result in sampling bias. However, there is no reason to believe that this 
sampling bias varies by time, so this is unlikely to account for the increases in potency ob-
served in global cannabis markets. Moreover, data collected in the Netherlands confirmed a 
strong increase in potency from 2000 to 2004 in cannabis randomly sampled directly from 
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retail outlets55. Secondly, few cannabis potency studies address the issue of price, despite its 
important role in purchasing behavior and consumption and the possibility of contrasting 
trends in different regions or markets.  pe Therefore in future studies, combining information 
on potency and price will be more informative than potency alone.  
While clinical studies involving adult populations can be useful in drawing conclusions from 
the effects of cannabis use, it can be difficult to generalize these findings to adolescents in the 
community. Moreover, unmeasured confounding variables are a limitation common to many 
observational studies, and there is only limited evidence from placebo-controlled, double-
blind studies51. For example, a major confound that is not adequately addressed in many stud-
ies to date is tobacco, which is frequently co-administered with cannabis, and has found to be 
associated with later incidents of psychosis56. Another major limitation that has been identi-
fied in this review is in relation to the measurement of cannabis use. Most studies evaluate 
the harms of cannabis use by employing duration and/or frequency, but neglect measures of 
cannabis potency or quantification of concentrations of THC and/or CBD. Self-reported data 
on potency may be limited by the wide range of THC and CBD concentrations within canna-
bis products. However, previous data has validated self-reported cannabis type against actual 
THC and CBD concentrations measured in the laboratory53. While laboratory tests are more 
precise, they are far less feasible for estimating long-term patterns of use (e.g. by repeatedly 
sampling an individual’s cannabis use across the lifespan). We would therefore recommend 
that the assessment of cannabis potency should accompany questions about frequency and 
duration in healthcare and research settings. Pictorial aids (as illustrated in Figure 1) and ver-
bal descriptions may be helpful for identifying different cannabis products. Moreover, re-
searchers should use laboratory tests to calculate precise concentrations of THC and CBD in 
cannabis where possible. Unlike standard units of alcohol used in alcohol literature, there are 
currently no agreed standards for measuring cannabis57. The use of standardized cannabis use 
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units could vastly improve our understanding of variation in cannabis use and its conse-
quences on adolescent health.  
Future research  
In light of the current research and its limitations, there are several avenues for future re-
search. As there is a gap in the research focusing on adolescence, there is also an absence of 
cognitive and neuroimaging measures when focusing on potency58. While some studies have 
taken brain imaging measures from cannabis users, they have either been restricted to the 
limitations associated with hair analysis or have not included supplementary cognitive 
measures59,60. Studies employing these measures, alongside an accurate measure of cannabis 
potency, would allow for a better understanding of the neurocognitive effects across different 
cannabis products, both long and short-term.  
With cannabis policy rapidly evolving, there is a possibility that further countries and states 
will legalise recreational cannabis use alongside existing US states and Canada. While it is 
important to recommend that age related restrictions for ultra-high potency products be 
guided by evidence based public health research it is acknowledged that the legal age of pur-
chase is often based on the legal age of purchase of alcohol. Furthermore, while current legal 
frameworks in the US allow for legal cannabis potency and price to be set by the market, pol-
icy makers should consider the implementation of THC unit taxes, or THC thresholds8. For 
example, if harm increases as the price per unit of THC decreases, setting an acceptable level 
of tax per THC unit may help minimize harm. By contrast, if the potency of cannabis prod-
ucts is more important (irrespective of price) then setting an upper limit on THC concentra-
tion may be more effective. Furthermore, in order to fully evaluate the health consequences 
of changes in cannabis use it will be essential to determine the extent to which cannabis may 
act as a substitute or a complement to other drugs such as tobacco or alcohol61. 
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Conclusion       
Given the growing body of research finding on cannabis potency and cannabis related harms, 
there is now a pressing need to understand how different types of cannabis products impact 
on adolescent health. Furthermore, a better understanding of the impact of cannabis use po-
tency on adolescent neurocognition and mental health could inform future prevention pro-











Panel 1: Cannabis prevention and information 
With changes in policy potentially making cannabis increasingly accessible to adolescents in 
several states and countries worldwide, effective prevention and information is critical. Ap-
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proximately half of all first-time cannabis use occurs before the age of 1862, and with evi-
dence suggesting that risk perception is more difficult to alter after first time use than be-
fore63, it is important that adolescents are targeted at an early age (regardless of differential 
risk of use)64. Furthermore, a Cochrane review reported that although existing information 
and prevention programs have resulted in small reductions in drug use, the most effective 
programs have been those that involve a combination of drug information, social skills train-
ing (e.g. goal-setting and decision making), and anti-drug resistance skills training65.  
Programs must also be evidence-based, yet despite this, those that include information on po-
tency or cannabis type are scarce. An internet delivered program, the Climate Schools, edu-
cated users on THC content. This program was efficacious in improving cannabis knowledge 
and reducing frequency of use66. Future prevention programs must allow for the discussion of 
how cannabis types differ in constituents, availability, risks, and harms so that adolescents 
are equipped with up-to-date evidence67, allowing for the prevention or delay of cannabis use 






Panel 2: Key messages 
Problematic cannabis use typically peaks in adolescents 2- )an age group that may be 
particularly vulnerable to its harmful effects 
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Cannabis markets are dominated by high potency cannabis (high THC; low CBD), with 
THC content steadily increasing worldwide 
Compared to low potency cannabis, high potency cannabis appears to be associated 
with a greater risk of psychotic symptoms, depression, anxiety and cannabis depend-
ence 
Adolescents only partially titrate their use of high potency cannabis, which can result in 
the consumption of high levels of THC. 
Alongside more accurate measures of cannabis potency, further research must adopt 
longitudinal, cognitive, and neuroimaging measures to gain a better understanding of 
the effects of adolescent cannabis use  
With cannabis policy rapidly changing, up-to-date evidence should inform decisions on 
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Search strategy and selection criteria 
The current literature review originated from a comprehensive search of the literature via 
PubMed, Google Scholar, and the author’s own files. The search involved key terms such as 
‘adolescence’, ‘cannabis’, ‘early-onset cannabis use’, ‘cannabis potency’, ‘cannabis harms’, 
and ‘delta-9-tetrahydrocannabiol, THC: Cannabidiol, CBD’. As research focusing on adoles-
cent cannabis use is scarce, the current review included English written articles published in 
the last 15 years (January 2003), with the exception of original citations for measurements 
(e.g. Stop-Signal task). Finally, the decision to include articles was based on the relevance 
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